Research article Special Issues

Highly dispersive gap solitons for conformable fractional model in optical fibers with dispersive reflectivity solutions using the modified extended direct algebraic method

  • Received: 19 July 2024 Revised: 16 August 2024 Accepted: 19 August 2024 Published: 28 August 2024
  • MSC : 26A33, 35C07, 35C08, 35C09

  • We investigated the dynamics of highly dispersive nonlinear gap solitons in optical fibers with dispersive reflectivity, utilizing a conformable fractional derivative model. The modified extended direct algebraic method was employed to obtain various soliton solutions, including bright solitons and singular solitons, as well as hyperbolic and trigonometric solutions. The key findings demonstrated that the fractional derivative parameter (α) can effectively control the wave propagation, causing a shift in the wave signal while maintaining the same amplitude. This is a novel contribution, as the ability to control soliton properties through the conformable derivative is explored for the first time in this work. The results showcase the significant influence of fractional derivatives in shaping the characteristics of the soliton solutions, which is crucial for accurately modeling the dispersive and nonlocal effects in optical fibers. This research provides insights into the potential applications of fractional calculus in the design and optimization of photonic devices for optical communication systems.

    Citation: Mahmoud Soliman, Hamdy M. Ahmed, Niveen Badra, Taher A. Nofal, Islam Samir. Highly dispersive gap solitons for conformable fractional model in optical fibers with dispersive reflectivity solutions using the modified extended direct algebraic method[J]. AIMS Mathematics, 2024, 9(9): 25205-25222. doi: 10.3934/math.20241229

    Related Papers:

    [1] Kholoud Baraka, Rania Abozahra, Maged Wasfy Helmy, Nada Salah El Dine El Meniawy, Sarah M Abdelhamid . Investigation of the protective and therapeutic effects of Lactobacillus casei and Saccharomyces cerevisiae in a breast cancer mouse model. AIMS Microbiology, 2022, 8(2): 193-207. doi: 10.3934/microbiol.2022016
    [2] Md. Aoulad Hosen, Fozol Korim Ovi, Harunur Rashid, MD. Hasibul Hasan, Md. Abdul Khalek, Mahmudul Hasan, Farhana Easmin, Nazmi Ara Rumi, Mohammad Shariful Islam . Characterization of Vibrio spp. in environmental water samples collected from flood prone areas of Bangladesh and their antibiotic resistance profile. AIMS Microbiology, 2021, 7(4): 471-480. doi: 10.3934/microbiol.2021028
    [3] Yue Tang, Shaun Cawthraw, Mary C. Bagnall, Adriana J. Gielbert, Martin J. Woodward, Liljana Petrovska . Identification of temperature regulated factors of Campylobacter jejuni and their potential roles in virulence. AIMS Microbiology, 2017, 3(4): 885-898. doi: 10.3934/microbiol.2017.4.885
    [4] Tatyana V. Polyudova, Daria V. Eroshenko, Vladimir P. Korobov . Plasma, serum, albumin, and divalent metal ions inhibit the adhesion and the biofilm formation of Cutibacterium (Propionibacterium) acnes. AIMS Microbiology, 2018, 4(1): 165-172. doi: 10.3934/microbiol.2018.1.165
    [5] Ashok Chakraborty, Anil Diwan, Jayant Tatake . Prospect of nanomaterials as antimicrobial and antiviral regimen. AIMS Microbiology, 2023, 9(3): 444-466. doi: 10.3934/microbiol.2023024
    [6] Arsenio M. Fialho, Nuno Bernardes, Ananda M Chakrabarty . Exploring the anticancer potential of the bacterial protein azurin. AIMS Microbiology, 2016, 2(3): 292-303. doi: 10.3934/microbiol.2016.3.292
    [7] Nieves Barros, Sergio Feijoo, César Pérez-Cruzado, Lee D. Hansen . Effect of soil storage at 4 °C on the calorespirometric measurements of soil microbial metabolism. AIMS Microbiology, 2017, 3(4): 762-773. doi: 10.3934/microbiol.2017.4.762
    [8] Paola Ortiz-Ojeda, Katty Ogata-Gutiérrez, Doris Zúñiga-Dávila . Evaluation of plant growth promoting activity and heavy metal tolerance of psychrotrophic bacteria associated with maca (Lepidium meyenii Walp.) rhizosphere. AIMS Microbiology, 2017, 3(2): 279-292. doi: 10.3934/microbiol.2017.2.279
    [9] Laurent Coquet, Antoine Obry, Nabil Borghol, Julie Hardouin, Laurence Mora, Ali Othmane, Thierry Jouenne . Impact of chlorhexidine digluconate and temperature on curli production in Escherichia coli—consequence on its adhesion ability. AIMS Microbiology, 2017, 3(4): 915-937. doi: 10.3934/microbiol.2017.4.915
    [10] MP Lizardo, FK Tavaria . Probiotic growth in skin-like conditions. AIMS Microbiology, 2022, 8(4): 388-402. doi: 10.3934/microbiol.2022027
  • We investigated the dynamics of highly dispersive nonlinear gap solitons in optical fibers with dispersive reflectivity, utilizing a conformable fractional derivative model. The modified extended direct algebraic method was employed to obtain various soliton solutions, including bright solitons and singular solitons, as well as hyperbolic and trigonometric solutions. The key findings demonstrated that the fractional derivative parameter (α) can effectively control the wave propagation, causing a shift in the wave signal while maintaining the same amplitude. This is a novel contribution, as the ability to control soliton properties through the conformable derivative is explored for the first time in this work. The results showcase the significant influence of fractional derivatives in shaping the characteristics of the soliton solutions, which is crucial for accurately modeling the dispersive and nonlocal effects in optical fibers. This research provides insights into the potential applications of fractional calculus in the design and optimization of photonic devices for optical communication systems.



    1. Introduction

    Parkinson’s disease (PD) is an incurable, progressive movement disorder affecting approximately one million Americans (www.pdf.org) and is the 14th leading cause of death in the US (www.cdc.gov). The pathogenesis of PD involves the degeneration of neurons, especially dopaminergic neurons in the substantia nigra of the midbrain [1], and the presence of Lewy bodies/neuritis in various brain regions [2]. Deficiency of the nigro-striatal pathways can cause dopamine depletion-specific symptoms such as motor dysfunctions and multiple non-motor clinical issues. The clinical diagnosis of PD is based on the four cardinal symptoms: tremor, rigidity, bradykinesia, and postural instability [3], which are delayed and subtle. Since the key pathology of PD occurs in the brainstem which is difficult to assess in living patients, it is challenging to monitor PD progression in an unbiased and objective manner. Thus, developing reliable clinical diagnostic methods that are feasible, objective, measurable, specific and sensitive for PD is essential to improve the clinical management of the disease.

    A molecular biomarker is a biological molecule found in blood, other bodily fluids or tissues that can be measured as an indicator of a normal or abnormal biological process, or of a disease condition. Molecular biomarkers can be used as a diagnostic or prognostic tool for a specific disease. In PD, biochemical biomarkers which are heavily based on alpha-synuclein (SNCA), the primary structural component of Lewy bodies, have been proposed in the past few years [4]. This mini review will focus on the most recent development of non-SNCA, microRNA (miRNA)-based biomarkers identified in various biofluids for PD diagnosis.

    2. miRNAs as informative biomarkers for specific diseases

    miRNAs are a family of short (18-22 nucleotides), single-stranded non-coding RNAs that act as gene expression modulators at the post-transcriptional level to fine-tune the expression of specific messenger RNAs (mRNAs) [5, 6]. Many miRNAs can target multiple mRNAs by recognizing short, specific complementary sequences in the mRNAs and control the expression of hundreds to thousands of genes [7, 8]. miRNA expression profiling has been used frequently to identify biomarkers and/or molecular pathways associated with specific human diseases. miRNAs are also known to be highly abundant, tissue-specific, quantifiable, highly stable with non-post process modification, which are “ideal” characteristics of biomarkers. In neurodegeneration, although the pathogenic mechanisms are complex and not fully defined, deregulation of miRNAs has been increasingly recognized to play important roles in the process [9]. There is also emerging evidence describing the important roles of miRNAs in neuronal processes such as neuronal differentiation and neuroplasticity. miRNAs as potential clinical biomarkers for PD has been described extensively in our previous review [10].

    3. Biofluids are excellent biomarker resources

    Biological fluids or biofluids are liquids originating from human bodies. They are an excellent source for biomarker research as their close proximity to cells can potentially reflect their biochemical contents and hence the biological conditions of the cells [11]. Common biofluids used in biomarker research include peripheral blood, blood serum or plasma, saliva, urine, and cerebral spinal fluid (CSF). Deregulation of blood miRNAs has been significantly correlated with disease-associated genetic variants [12]. Since biofluid sample collection is inexpensive, rapid, simple, and minimally invasive (except for CSF), it has a large advantage over other solid or semi-solid biospecimens for studying disease biomarkers.

    4. miRNAs detection in peripheral blood of PD patients

    Blood is an ideal source for biomarkers because it can be obtained in a simple, fast, low-cost and minimally invasive manner. The first report of peripheral blood-based miRNA biomarkers for PD was demonstrated in 2011 by a quantitative real-time PCR (qRT-PCR) approach [13]. A set of 3 miRNAs (miR-1, miR-22*, and miR-29a) with lower miRNA expression was identified when compared between de novo and treated PD vs. control and early-onset PD. A second set of 3 miRNAs (miR-16-2*, miR-26a2*, and miR-30a) showed 50% higher expression in treated PD vs. control subjects (Table 1). The second report applied a microarray approach to identify 18 under-expressed miRNAs in peripheral blood mononuclear cells of PD vs. control [14]. The third report used a combination of small RNA next-generation sequencing (small RNA-seq) and exon microarray technologies to investigate miRNA expression in blood leukocytes (white blood cells) of healthy controls as well as PD patients before and after deep brain stimulation (DBS) treatment [15]. A set of 5 miRNAs (miR-4293, miR-378c, miR-18b*, miR-20a, and miR-1249) that are under-expressed in PD vs. DBS has inversed/higher expression in controls whe n compared with PD, suggesting both treatment and disease related changes in miRNA expression. Interestingly, down-regulation of miR-29a, miR-29c, miR-30c, and miR-19b can also be observed in white blood cells of PD DBS-off vs. DBs-on patients and/or in the serum of PD vs. control (see Table 1 and cmiRNAs in plasma/serum section below). Unfortunately, detection sensitivity of miRNA expression among biofluid types (i.e., peripheral blood vs. mononuclear cells vs. white blood cells vs. serum) could not be evaluated mainly due to different technologies (i.e.,qRT-PCT, microarray and next-generation sequencing) used among these studies.

    Table 1. Biofluid-based miRNA expression studies in Parkinson’s disease.
    miRNA Biofluid type Sample size Sample type Method Reference
    ↓ miR-29a Peripheral blood White blood cells Serum 15 PD vs. 8 CTR 7 PD vs. 6 CTR Discovery set: 10 PD, 10 LRRK2 PD vs. 10 CTR Validation set 1: 20 PD, 20 LRRK2 PD vs. 20 CTR Validation set 2: 65 PD vs. 65 CTR de novo PD + levodopa/carbidopa treated vs. CTR + early onset PD PD (DBS-off) vs. PD (DBS-on) PD vs. CTR qRT-PCR (SYBR green) Small RNA-sequencing (ABI SOLiD) TaqMan Low Density miRNA array v.2.0 A, validation by qRT-PCR (TaqMan) Margis et al., 2011 Soreq et al., 2013 Botta-Orfila et al., 2014
    ↓ miR-29c Peripheral blood mononuclear cell White blood cell Serum 19 PD vs.13 CTR 7 PD vs. 6 CTR Discovery set: 10 PD, 10 LRRK2 PD vs. 10 CTR Validation set 1: 20 PD, 20 LRRK2 PD vs. 20 CTR Validation set 2: 65 PD vs. 65 CTR PD vs. CTR PD (DBS-off) vs. PD (DBS-on) PD vs. CTR Exiqon miRCURY LNA array v.10.0, validation by qRT-PCR (TaqMan) Small RNA-sequencing (ABI SOLiD) TaqMan Low Density miRNA array v.2.0 A, validation by qRT-PCR (TaqMan) Martins et al., 2011 Soreq et al., 2013 Botta-Orfila et al., 2014
    ↓ miR-30c Peripheral blood mononuclear cell Serum 19 PD vs.13 CTR Discovery set: 6 PD, 6 MSA-P, 3 MSA-C vs. 5 CTR Validation set: 25 PD, 25 MSA, vs. 25 CTR PD vs. CTR PD vs. CTR Exiqon miRCURY LNA array v.10.0, validation by qRT-PCR (TaqMan) TaqMan Low Density miRNA array v.3.0 A and B, validation by qRT-PCR (TaqMan) Martins et al., 2011 Vallelunga et al., 2014
    ↓ miR-19b Peripheral blood mononuclear cell Serum 19 PD vs.13 CTR Discovery set: 10 PD, 10 LRRK2 PD vs. 10 CTR Validation set 1: 20 PD, 20 LRRK2 PD vs. 20 CTR Validation set 2: 65 PD vs. 65 CTR PD vs. CTR PD vs. CTR Exiqon miRCURY LNA array v.10.0, validation by qRT-PCR (TaqMan) TaqMan Low Density miRNA array v.2.0 A, validation by qRT-PCR (TaqMan) Martins et al., 2011 Botta-Orfila et al., 2014
    ↓ miR-1, miR-22* ↑ miR-16-2*, miR-26a2*, miR-30a Peripheral blood 15 PD vs. 8 CTR de novo PD + levodopa/carbidopa treated vs. CTR + early onset PD levodopa/carbidopa treated vs. CTR qRT-PCR (SYBR green) Margis et al., 2011
    ↓ miR-335, miR-374a, miR-199a-3p/miR-199b-3p, miR-126*, miR-151-3p, miR-199a-5p, miR-151-5p, miR-126, miR-29b, miR-147, miR-28-5p, miR-30b, miR-374b, miR-301a, miR-26a Peripheral blood mononuclear cell 19 PD vs.13 CTR PD vs. CTR Exiqon miRCURY LNA array v.10.0, validation by qRT-PCR (TaqMan) Martins et al., 2011
    ↓ miR-320a/b/c, miR-769, miR-92b, miR-16 ↑ miR-199b, miR-1274b, miR-21, miR-150, miR-671, miR-1249, miR-20a, miR-18b*, miR-378c, miR-4293 ↓ miR-4293, miR-378c, miR-18b*, miR-424*, miR-20a, miR-210, miR-1249, miR-93 ↑ miR-4317, miR-143, miR-424 ↓ miR-652, miR-15a*, miR-376c, miR-143 ↑ miR-423, miR-365, miR-486, miR-1260, miR-218 White blood cell 7 PD vs. 6 CTR PD (pre-DBS) vs. CTR PD (pre-DBS) vs. PD (post-DBS) PD (DBS-off) vs PD (DBS-on) Small RNA-sequencing (ABI SOLiD) Soreq et al., 2013
    A panel of four miRNA biomarkers ↑ miR-1826, ↓ miR-450b-3p ↑ miR-626, miR-505 Plasma Discovery set: 32 PD vs.32 CTR Replication set: 42 PD vs.30 CTR Validation set: 30 PD, 4 MSA, 5 PSP vs. 8 CTR PD (treated) vs. CTR Agilent miRNA microarray v.3, validation by qRT-PCR (TaqMan) Khoo et al., 2012
    ↑ miR-331-5p Plasma 31 PD vs. 25 CTR PD (non-treated) vs. CTR TaqMan Low Density miRNA array (3 pools of PD and CTR), then qRT-PCR (TaqMan) Cardo et al., 2013
    ↓ miR-339-5p ↑ miR-223*, miR-324-3p, miR-24 ↓ miR-148b ↑ miR-223*, miR-324-3p, miR-24 Serum Discovery set: 6 PD, 6 MSA-P, 3 MSA-C vs. 5 CTR Validation set: 25 PD, 25 MSA, vs. 25 CTR PD + MSA vs. CTR PD vs. CTR TaqMan Low Density miRNA array v.3.0 A and B, validation by qRT-PCR (TaqMan) Vallelunga et al., 2014
    ↓ miR-19a Serum Discovery set: 10 PD, 10 LRRK2 PD vs. 10 CTR Validation set 1: 20 PD, 20 LRRK2 PD vs. 20 CTR Validation set 2: 65 PD vs. 65 CTR PD vs. CTR TaqMan Low Density miRNA array v.2.0 A, validation by qRT-PCR (TaqMan) Botta-Orfila et al., 2014
    ↓ miR-16-2-3p, miR-1294 ↑ miR-338-3p, miR-30e-3p, miR-30a-3p ↓ miR-132-5p, miR-485-5p, miR-127-3p, miR-128, miR-409-3p, miR-433, miR-370, miR-431-3p, miR-873-3p, miR-136-3p, miR-212-3p, miR-10a-5p, miR-1224-5p, miR-4448 ↑ miR-19a-3p, miR-19b-3p, let-7g-3p Serum (post mortem) CSF (post mortem) 50 PD vs. 62 CTR 57 PD vs. 65 CTR PD vs. CTR PD vs. CTR Small RNA Sequencing (Illumina HiSeq2000) Burgos et al., 2014
    PD: Parkinson’s disease; CTR: healthy control; PSP: progressive supranuclear palsy; MSA: multiple system atrophy; LRRK2 PD: G2019S mutation in PD;
    DBS: Deep brain stimulation; ↓: down-regulated miRNA expression; ↑: up-regulated miRNA expression.
     | Show Table
    DownLoad: CSV

    5. The potential of circulating miRNAs (cmiRNAs) as disease-related biomarkers

    The presence of circulating miRNAs (cmiRNAs) was first described in the serum of diffuse large B-cell lymphoma patients [16]. Since then, many studies have shown that miRNAs exist not only at the cellular level but also as circulating, cell-free miRNAs in serum, plasma, and CSF. There are several hypotheses of how cmiRNAs can be released into circulatory systems: 1) direct leakage of cellular miRNAs as by-products of tissue damage or apoptosis due to certain pathological conditions (such as metastasis or inflammation), 2) active secretion by cells as free miRNAs with or without cell stimulation, and 3) secretion in the form of cell-derived microvesicles (eg. microparticles and exosomes), apoptotic bodies, miRNA-protected proteins (eg. Ago2 and NPM1) or high-density lipoprotein [17, 18, 19, 20, 21, 22].

    Similar to miRNAs, cmiRNAs are highly stable and resistant to RNase activity, extreme pH and temperature [23, 24]. cmiRNA expression are also known to correlate with various human diseases, especially cancers [17]. In PD, we performed a proof-of-concept study and first reported a panel of four cmiRNA as potential PD biomarkers [25]. With high stability and capacity to reflect disease status, cmiRNAs have great potential as molecular biomarkers for diagnosis and prognosis of neurodegenerative diseases. Readers can further refer to a review by Sheinerman and Umansky [26] on cmiRNAs biomarkers for various neurodegenerative diseases and three common approaches used for such studies. In Alzheimer’s disease (AD), miRNA expression changes in brain and CSF have provided insights into the disease pathways [27]. Therefore, besides their utility as disease biomarkers, cmiRNA may provide new insights for the pathogenesis of PD.

    6. Identification of cmiRNA biomarkers in blood plasma/serum for PD

    We published the first report of four plasma-based cmiRNAs (miR-1826, miR-450b-3p, miR-626, and miR-505) as a panel of potential biomarkers for PD using Agilent microarrays followed by a qRT-PCR approach [25]. A validation study using a new, independent cohort has been carried out to confirm the reproducibility and robustness of these candidate biomarkers. One year later, another group used the TaqMan low-density microarray cards and qRT-PCR and found miR-331-5 significantly up-regulated in plasma of PD patients compared with healthy controls [28]. Both findings are mutually exclusive and could be explained by used of 1) different discovery platforms which may have different detection sensitivities, 2) different statistical algorithms to identify differentially-expressed cmiRNAs, and 3) treated PD patients in the formal and naïve PD patients in the later report.

    Recently, three additional studies on serum-based cmiRNA biomarkers for PD have been reported. Four differentially-expressed cmiRNAs (miR-399-5p, miR-223*, miR-324-3p, and miR-24) were identified and validated in PD and MSA (multiple system atrophy) vs. control subjects [29]. The same cmiRNAs (except miR-339-5p) were identified in PD vs. control, in addition to miR-30c and miR-148b which were down-regulated. Interestingly, miR-30c was also found down-regulated in the peripheral blood mononuclear cell of PD when compared with control. Another report used PD and LRRK2 (leucine-rich repeat kinase 2) PD as discovery and first validation cohort to identify 4 statistically significant cmiRNAs (miR-29a, miR-29c, miR-19a, and miR-19b) in PD vs. control in a second validation study [30]. Strikingly, down-regulation of miR-29a, miR-29c, miR-30c, and miR-19b were also shown in previous blood-based biomarker studies [13, 14]. Repeated detection of similar miRNAs regardless of biofluid types and detection technologies make these miRNAs strong biofluid-based biomarker candidates for PD which need to be validated. In another miRNA expression profiling study using small next-generation sequencing on post mortem sera, 5 differentially-expressed cmiRNAs were identified between PD and control [31].

    7. cmiRNA expression is altered in PD’s CSF

    Small RNA-seq was also recently used to detect 17 differentially-expressed cmiRNAs in post mortem CSF of PD or AD patients vs. healthy controls [31]. Although one differentially-expressed cmiRNA was identified in both CSF and serum for AD, there was no overlapping cmiRNA candidate in CSF and serum from the same PD patients. This finding suggests that cmiRNA expression in serum may not be corresponding to those in CSF which is directly connected to the central nervous system; CSF and serum may not provide similar cmiRNA expression profiles in this case. Moreover, the viability of cmiRNA expression in postmortem vs. fresh serum and CSF is relatively unknown and worth investigation.

    Table 1 summarizes the biofluid-based miRNA studies for PD mentioned above.

    8. Current limitations of biofluid-based miRNA biomarkers

    Biofluid-based miRNA biomarker research for PD has been emerging rapidly. cmiRNAs are envisioned to become potential biomarkers for early detection and progression of PD. However, there are several impeding factors that may come into play. First, miRNAs usually exist in much lower amounts in biofluids than tissues. Hence, depending on the sensitivity of the detection techniques, they can remain undetected and be missed as potential biomarkers. Fortunately, recent advancements of non-biased amplification and enrichment techniques have substantially improved the detection sensitivity of miRNA expression. Second, biomarker research is known for its complexity and difficulty in correlating different biomarker data from different reports. As shown in Table 1, biomarkers in bodily fluids are screened and analyzed by a variety of techniques. Variations may also involve sample collection and storage, sample preparation, data normalization and data analysis [10]. Therefore, a unifying method and/or technique should be applied for each specific biomarker in general. However, in a “real-world” clinical setting, standardization from the beginning of sample collection to assay processes may not be feasible or realistic. This also brings us to the third limitation where either small or no validation studies were performed to confirm the reproducibility and robustness of these biofluid-based biomarker candidates and its assays; this drawback has further delayed the incorporation of molecular biomarkers into routine preclinical or clinical applications. Fourth, the presence of miRNAs in biological fluids as a disease indicator remains a subject of considerable debate. Although deregulation of miRNAs has been increasingly recognized to play important roles in neurodegeneration [9], the potential of utilizing miRNAs to reflect pathogenic changes in the brain needs to be further investigated and validated.

    9. Future perspectives

    This mini review shows that miRNAs in bodily fluids hold promise as potential molecular biomarkers for PD. Unique characteristics of miRNAs and cmiRNAs make them highly attractive as molecular biomarkers. Follow-up validation studies and standardization are critical to ensure successful development of sensitive and specific biomarkers for PD. The finding of stable cmiRNAs in biofluids suggests their possible function as mediators in cell-cell communication in response to biological stimuli [32]. Thus, it is possible that cmiRNAs in serum or plasma may directly or indirectly reflect the pathological status of the brain. It is also known that miRNAs can be transported by exosomes which are lipid microvesicles of endocytic origin secreted by many cell types, including neurons, astrocytes, oligodendrocytes, and microglia [33, 34, 35, 36]. Recent evidence has shown the involvement of exosomes in the pathogenesis of PD [37]. Although the association of exosome-based miRNAs in neurodegeneration has not been established, it is worth future investigation.

    In AD, cmiRNAs in CSF and serum have been identified to correlate with the severity of disease such as Braak stages, neurofibrillary tangle and plaque-density scores [27, 31]. Hence, future investigation of cmiRNA expression in correlation with PD severity (e.g. SNCA accumulation or Lewy bodies) may accelerate discovery of progression biomarkers for PD. In summary, establishing and validating biofluid-based miRNA biomarkers may facilitate the development of objective diagnostic and prognostic molecular tools for PD to translate basic research discovery to clinical setting.

    Acknowledgements

    S.K. Khoo is supported by grants from the Michael J. Fox Foundation for Parkinson’s Research.

    Conflict of interest

    All authors declare no conflict of interest.



    [1] W. B. Rabie, H. M. Ahmed, A. R. Seadawy, A. Althobaiti, The higher-order nonlinear Schrödinger's dynamical equation with fourth-order dispersion and cubic-quintic nonlinearity via dispersive analytical soliton wave solutions, Opt. Quant. Electron., 53 (2021), 6868. http://doi.org/10.1007/s11082-021-03278-z doi: 10.1007/s11082-021-03278-z
    [2] I. Samir, H. M. Ahmed, M. Mirzazadeh, H. Triki, Derivation of new solitons and other solutions for higher order Sasa–Satsuma equation by using the improved modified extended tanh scheme, Optik, 274 (2023), 170592. http://doi.org/10.1016/j.ijleo.2023.170592 doi: 10.1016/j.ijleo.2023.170592
    [3] Y.-L. Ma, B.-Q. Li, The dynamics on soliton molecules and soliton bifurcation for an extended generalization of Vakhnenko equation, Qual. Theory Dyn. Syst., 23 (2024), 137. http://doi.org/10.1007/s12346-024-01002-2 doi: 10.1007/s12346-024-01002-2
    [4] B.-Q. Li, A.-M. Wazwaz, Y.-L. Ma, Soliton resonances, soliton molecules to breathers, semi-elastic collisions and soliton bifurcation for a multi-component Maccari system in optical fiber, Opt. Quant. Electron., 56 (2024), 573. http://doi.org/10.1007/s11082-023-06224-3 doi: 10.1007/s11082-023-06224-3
    [5] Y.-L. Ma, B.-Q. Li, Interaction behaviors between solitons, breathers and their hybrid forms for a short pulse equation, Qual. Theory Dyn. Syst., 22 (2023), 146. http://doi.org/10.1007/s12346-023-00844-6 doi: 10.1007/s12346-023-00844-6
    [6] Y.-L. Ma, B.-Q. Li, Optical soliton resonances, soliton molecules to breathers for a defocusing Lakshmanan–Porsezian–Daniel system, Opt. Quant. Electron., 56 (2024), 151. http://doi.org/10.1007/s11082-023-05687-8 doi: 10.1007/s11082-023-05687-8
    [7] Y.-L. Ma, B.-Q. Li, Higher-order hybrid rogue wave and breather interaction dynamics for the AB system in two-layer fluids, Math. Comput. Simul., 221, 489–502. https://doi.org/10.1016/j.matcom.2024.03.017
    [8] Y.-L. Ma, B.-Q. Li, Soliton interactions, soliton bifurcations and molecules, breather molecules, breather-to-soliton transitions, and conservation laws for a nonlinear (3+1)-dimensional shallow water wave equation, Nonlinear Dyn., 112 (2024), 2851–2867. http://doi.org/10.1007/s11071-023-09185-0 doi: 10.1007/s11071-023-09185-0
    [9] C. Guo, B. Guo, The existence of global solutions for the fourth-order nonlinear Schrödinger equations, J. Appl. Anal. Comput., 9 (2019), 1183–1192. http://doi.org/10.11948/2156-907X.20190095 doi: 10.11948/2156-907X.20190095
    [10] R. Kohl, A. Biswas, D. Milovic, E. Zerrad, Adiabatic dynamics of Gaussian and super-Gaussian solitons in dispersion-managed optical fibers, Prog. Electromagn. Res., 84 (2008), 27–53. http://doi.org/10.2528/PIER08052703 doi: 10.2528/PIER08052703
    [11] A.-M. Wazwaz, W. Alhejaili, S. A. El-Tantawy, Bright and dark envelope optical solitons for a (2+1)-dimensional cubic nonlinear Schrödinger equation, Optik, 265 (2022), 169525. http://doi.org/10.1016/j.ijleo.2022.169525 doi: 10.1016/j.ijleo.2022.169525
    [12] A.-M. Wazwaz, W. Alhejaili, A. O. AL-Ghamdi, S. A. El-Tantawy, Bright and dark modulated optical solitons for a (2+1)-dimensional optical Schrödinger system with third-order dispersion and nonlinearity, Optik, 274 (2023), 170582. http://doi.org/10.1016/j.ijleo.2023.170582 doi: 10.1016/j.ijleo.2023.170582
    [13] K. K. Ahmed, N. M. Badra, H. M. Ahmed, W. B. Rabie, Soliton solutions and other solutions for Kundu–Eckhaus equation with quintic nonlinearity and Raman effect using the improved modified extended tanh-function method, Mathematics, 10 (2022), 4203. http://doi.org/10.3390/math10224203 doi: 10.3390/math10224203
    [14] Y. Alhojilan, H. M. Ahmed, Novel analytical solutions of stochastic Ginzburg-Landau equation driven by Wiener process via the improved modified extended tanh function method, Alexandria Eng. J., 72 (2023), 269–274. http://doi.org/10.1016/j.aej.2023.02.016 doi: 10.1016/j.aej.2023.02.016
    [15] W. B. Rabie, H. M. Ahmed, Construction of cubic-quartic solitons in optical metamaterials for the perturbed twin-core couplers with Kudryashov's sextic power law using extended F-expansion method, Chaos, Soliton. Fract., 160 (2022), 112289. http://doi.org/10.1016/j.chaos.2022.112289 doi: 10.1016/j.chaos.2022.112289
    [16] T. A. Khalil, N. Badra, H. M. Ahmed, W. B. Rabie, Bright solitons for twin-core couplers and multiple-core couplers having polynomial law of nonlinearity using Jacobi elliptic function expansion method, Alexandria Eng. J., 61 (2022), 11925–11934. https://doi.org/10.1016/j.aej.2022.05.042 doi: 10.1016/j.aej.2022.05.042
    [17] M. Soliman, H. M. Ahmed, N. Badra, I. Samir, Effects of fractional derivative on fiber optical solitons of (2+1) perturbed nonlinear Schrödinger equation using improved modified extended tanh-function method, Opt. Quant. Electron., 56 (2024), 777. https://doi.org/10.1007/s11082-024-06593-3 doi: 10.1007/s11082-024-06593-3
    [18] F. Lederer, G. I. Stegeman, D. N. Christodoulides, G. Assanto, M. Segev, Y. Silberberg, Discrete solitons in optics, Phys. Rep., 463 (2008), 1–126. https://doi.org/10.1016/j.physrep.2008.04.004 doi: 10.1016/j.physrep.2008.04.004
    [19] M. Soliman, H. M. Ahmed, N. Badra, I. Samir, Dispersive perturbations of solitons for conformable fractional complex Ginzburg–Landau equation with polynomial law of nonlinearity using improved modified extended tanh-function method, Opt. Quant. Electron., 56 (2024), 1084. http://doi.org/10.1007/s11082-024-07018-x doi: 10.1007/s11082-024-07018-x
    [20] M. A. Arefin, U. Sadiya, M. Inc, M. H. Uddin, Adequate soliton solutions to the space–time fractional telegraph equation and modified third-order KdV equation through a reliable technique, Opt. Quant. Electron., 54 (2022), 309. https://doi.org/10.1007/s11082-022-03640-9 doi: 10.1007/s11082-022-03640-9
    [21] U. H. M. Zaman, M. A. Arefin, M. A. Akbar, M. H. Uddin, Explore dynamical soliton propagation to the fractional order nonlinear evolution equation in optical fiber systems, Opt. Quant. Electron., 55 (2023), 1295. https://doi.org/10.1007/s11082-023-05474-5 doi: 10.1007/s11082-023-05474-5
    [22] M. A. Arefin, U. H. M. Zaman, M. H. Uddin, M. Inc, Consistent travelling wave characteristic of space–time fractional modified Benjamin–Bona–Mahony and the space-time fractional Duffing models, Opt. Quant. Electron., 56 (2024), 588. https://doi.org/10.1007/s11082-023-06260-z doi: 10.1007/s11082-023-06260-z
    [23] U. H. M. Zaman, M. A. Arefin, M. A. Akbar, M. H. Uddin, Study of the soliton propagation of the fractional nonlinear type evolution equation through a novel technique, PLOS ONE, 18 (2023), e0285178. http://doi.org/10.1371/journal.pone.0285178 doi: 10.1371/journal.pone.0285178
    [24] M. A. Arefin, M. A. Khatun, M. S. Islam, M. A. Akbar, M. H. Uddin, Explicit soliton solutions to the fractional order nonlinear models through the Atangana beta derivative, Int. J. Theor. Phys., 62 (2023), 134. https://doi.org/10.1007/s10773-023-05400-1 doi: 10.1007/s10773-023-05400-1
    [25] A. Podder, M. A. Arefin, M. A. Akbar, M. H. Uddin, A study of the wave dynamics of the space-time fractional nonlinear evolution equations of beta derivative using the improved Bernoulli sub-equation function approach, Sci. Rep., 13 (2023), 20478. https://doi.org/10.1038/s41598-023-45423-6 doi: 10.1038/s41598-023-45423-6
    [26] E. M. E. Zayed, M. E. M. Alngar, R. Shohib, A. Biswas, Y. Yıldırım, C. M. Balanica Dragomir, Highly dispersive gap solitons in optical fibers with dispersive reflectivity having parabolic-nonlocal nonlinearity, Ukr. J. Phys. Opt., 25 (2024), 01033–01044.
    [27] W. A. Faridi, M. Iqbal, M. B. Riaz, S. A. AlQahtani, A.-M. Wazwaz, The fractional soliton solutions of dynamical systems arising in plasma physics: A comparative analysis, Alexandria Eng. J., 95 (2024), 247–261. https://doi.org/10.1016/j.aej.2024.03.061 doi: 10.1016/j.aej.2024.03.061
    [28] A. Kajouni, A. Chafiki, K. Hilal, M. Oukessou, A new conformable fractional derivative and applications, Int. J. Differ. Eq., 2021 (2021), 6245435. http://doi.org/10.1155/2021/6245435 doi: 10.1155/2021/6245435
    [29] M. B. Hubert, G. Betchewe, M. Justin, S. Y. Doka, K. T. Crepin, A. Biswas, et al., Optical solitons with Lakshmanan–Porsezian–Daniel model by modified extended direct algebraic method, Optik, 162 (2018), 228–236. https://doi.org/10.1016/j.ijleo.2018.02.091 doi: 10.1016/j.ijleo.2018.02.091
    [30] M. H. Ali, H. M. El-Owaidy, H. M. Ahmed, A. A. El-Deeb, I. Samir, Optical solitons and complexitons for generalized Schrödinger–Hirota model by the modified extended direct algebraic method, Opt. Quant. Electron., 55 (2023), 675. https://doi.org/10.1007/s11082-023-04962-y doi: 10.1007/s11082-023-04962-y
    [31] M. Bilal, J. Iqbal, R. Ali, F. A. Awwad, E. A. A. Ismail, Exploring families of solitary wave solutions for the fractional coupled Higgs system using modified extended direct algebraic method, Fractal Fract., 7 (2023), 653. http://doi.org/10.3390/fractalfract7090653 doi: 10.3390/fractalfract7090653
    [32] I. Samir, N. Badra, H. M. Ahmed, A. H. Arnous, Solitons dynamics in optical metamaterial with quadratic–cubic nonlinearity using modified extended direct algebraic method, Optik, 243 (2021), 166851. http://doi.org/10.1016/j.ijleo.2021.166851 doi: 10.1016/j.ijleo.2021.166851
    [33] O. El-Shamy, R. El-Barkouky, H. M. Ahmed, W. Abbas, I. Samir, Extraction of solitons in magneto–optic waveguides for coupled NLSEs with Kudryashov's law of nonlinearity via modified extended direct algebraic method, Ain Shams Eng. J., 15 (2024), 102477. https://doi.org/10.1016/j.asej.2023.102477 doi: 10.1016/j.asej.2023.102477
  • This article has been cited by:

    1. Saleh Khoshnood, Mehdi Tavalla, Mohammad Ali Mohaghegh, Faham Khamesipour, Seyed Hossein Hejazi, Genetic diversity of Leishmania major strains isolated from Phlebotomus papatasi and Phlebotomus alexandri in western Iran based on minicircle kDNA, 2021, 0971-7196, 10.1007/s12639-021-01369-y
    2. Alfredo Juarez-Saldivar, Rogelio Gómez-Escobedo, Gerardo Corral-Ruiz, Karla Fabiola Chacón-Vargas, Vanessa Horta-Montaño, Luvia Sanchez-Torres, Lenci k. Vazquez-Jimenez, Benjamín Nogueda-Torres, Gildardo Rivera, Repositioning FDA-Approved Drug Against Chagas Disease and Cutaneous Leishmaniosis by Structure-Based Virtual Screening, 2024, 55, 01884409, 102958, 10.1016/j.arcmed.2024.102958
    3. Andrea Lafleur, Stephane Daffis, Charles Mowbray, Byron Arana, Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis, 2024, 12, 2076-393X, 1179, 10.3390/vaccines12101179
    4. Anindita Bhattacharjee, Arka Bagchi, Solanki Sarkar, Sriparna Bawali, Arijit Bhattacharya, Arunima Biswas, Repurposing approved protein kinase inhibitors as potent anti-leishmanials targeting Leishmania MAP kinases, 2024, 351, 00243205, 122844, 10.1016/j.lfs.2024.122844
  • Reader Comments
  • © 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1122) PDF downloads(48) Cited by(3)

Article outline

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog